Phaseline

Targets › MT-ND4L

MT-ND4L (NADH-ubiquinone oxidoreductase chain 4L): drug programs, companies and trials

1 program from 1 company in 23 trials: 11 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4; Neurology, Cardiovascular, Genitourinary.

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Part of the enzyme membrane arm which is embedded in the lipid bilayer and involved in proton translocation. (UniProt, P03901)

Open in Phaseline: the race on MT-ND4L, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boryung PharmaceuticalMetformin Hydrochloride
Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor
MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6Phase 1Diabetes Mellitus; Diabete Mellitus; Depression; Polycystic Ovary Syndrome …–

Conditions

Anatomic Stage I Breast Cancer AJCC v8 (2) Erythroplakia (2) Diabetes Mellitus (1) Diabete Mellitus (1) Depression (1) Polycystic Ovary Syndrome (1) Breast Atypical Ductal Hyperplasia (1) Non Small Cell Lung Cancer (1) Medulloblastoma, Childhood (1) Pre-Eclampsia Onset Less Than 37 Weeks (1) Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia (1) Lung Carcinoma (1)

Modalities

small molecule (1)

Companies

Boryung Pharmaceutical (1)

Related targets

MT-ND6 (1) NDUFA10 (1) NDUFS8 (1) NDUFA6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.